JP2011500763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500763A5 JP2011500763A5 JP2010530462A JP2010530462A JP2011500763A5 JP 2011500763 A5 JP2011500763 A5 JP 2011500763A5 JP 2010530462 A JP2010530462 A JP 2010530462A JP 2010530462 A JP2010530462 A JP 2010530462A JP 2011500763 A5 JP2011500763 A5 JP 2011500763A5
- Authority
- JP
- Japan
- Prior art keywords
- indol
- dihydro
- ethyl
- acetamide
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 4
- 206010022437 insomnia Diseases 0.000 claims 4
- 230000001193 melatoninergic effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000027559 Appetite disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- BEGUCBIBFPEXBJ-UHFFFAOYSA-N 1-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]cyclopropane-1-carboxamide Chemical compound C12=CC(OC)=CC=C2CCN1CCC1(C(N)=O)CC1 BEGUCBIBFPEXBJ-UHFFFAOYSA-N 0.000 claims 1
- FZIOCLNQSSZLEQ-UHFFFAOYSA-N 1-[2-[6-(2-phenylethoxy)-2,3-dihydroindol-1-yl]ethyl]cyclopropane-1-carboxamide Chemical compound C1CC2=CC=C(OCCC=3C=CC=CC=3)C=C2N1CCC1(C(=O)N)CC1 FZIOCLNQSSZLEQ-UHFFFAOYSA-N 0.000 claims 1
- PWBULZJYQSUOIV-UHFFFAOYSA-N 1-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]cyclopropane-1-carboxamide Chemical compound C1CC2=CC=C(OCCCC=3C=CC=CC=3)C=C2N1CCC1(C(=O)N)CC1 PWBULZJYQSUOIV-UHFFFAOYSA-N 0.000 claims 1
- VGEGJTNFJKGJSG-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2CCN(CCNC(=O)C(F)(F)F)C2=C1 VGEGJTNFJKGJSG-UHFFFAOYSA-N 0.000 claims 1
- VUEUYLMHINPZCP-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C(F)(F)F)CCC2=CC=C1OCCCC1=CC=CC=C1 VUEUYLMHINPZCP-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 150000002476 indolines Chemical class 0.000 claims 1
- HTQZTNCKIQGQLW-UHFFFAOYSA-N n-[2-(5-bromo-6-methoxy-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound C1=C(Br)C(OC)=CC2=C1CCN2CCNC(C)=O HTQZTNCKIQGQLW-UHFFFAOYSA-N 0.000 claims 1
- LRSCUDLZEOJNEN-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2CCN(CCNC(C)=O)C2=C1 LRSCUDLZEOJNEN-UHFFFAOYSA-N 0.000 claims 1
- SAUVZPBRAOWWHN-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2N(CCNC(=O)CC)CCC2=C1 SAUVZPBRAOWWHN-UHFFFAOYSA-N 0.000 claims 1
- BTDOHXZTYNXNBL-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydroindol-1-yl)propyl]acetamide Chemical compound COC1=CC=C2CCN(C(C)CNC(C)=O)C2=C1 BTDOHXZTYNXNBL-UHFFFAOYSA-N 0.000 claims 1
- DCNUJKSLBGXCCL-UHFFFAOYSA-N n-[2-(6-methoxy-3-methyl-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2C(C)CN(CCNC(C)=O)C2=C1 DCNUJKSLBGXCCL-UHFFFAOYSA-N 0.000 claims 1
- BBCSQPHKBFZMRF-UHFFFAOYSA-N n-[2-(6-methoxy-5-phenyl-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=2N(CCNC(C)=O)CCC=2C=C1C1=CC=CC=C1 BBCSQPHKBFZMRF-UHFFFAOYSA-N 0.000 claims 1
- KVBUIYXZHDWRSA-UHFFFAOYSA-N n-[2-(6-methoxy-5-pyridin-4-yl-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=2N(CCNC(C)=O)CCC=2C=C1C1=CC=NC=C1 KVBUIYXZHDWRSA-UHFFFAOYSA-N 0.000 claims 1
- LIGFXOOCMXHVFZ-UHFFFAOYSA-N n-[2-[6-(2-phenylethoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C)CCC2=CC=C1OCCC1=CC=CC=C1 LIGFXOOCMXHVFZ-UHFFFAOYSA-N 0.000 claims 1
- NNMKLYXVTDXENJ-UHFFFAOYSA-N n-[2-[6-(2-phenylethoxy)-2,3-dihydroindol-1-yl]ethyl]propanamide Chemical compound C1=C2N(CCNC(=O)CC)CCC2=CC=C1OCCC1=CC=CC=C1 NNMKLYXVTDXENJ-UHFFFAOYSA-N 0.000 claims 1
- TVOQLWJVRZIPPM-UHFFFAOYSA-N n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C)CCC2=CC=C1OCCCC1=CC=CC=C1 TVOQLWJVRZIPPM-UHFFFAOYSA-N 0.000 claims 1
- GXCQXEGURQQACG-UHFFFAOYSA-N n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]butanamide Chemical compound C1=C2N(CCNC(=O)CCC)CCC2=CC=C1OCCCC1=CC=CC=C1 GXCQXEGURQQACG-UHFFFAOYSA-N 0.000 claims 1
- HRDIWAMPNHYPTG-UHFFFAOYSA-N n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]propanamide Chemical compound C1=C2N(CCNC(=O)CC)CCC2=CC=C1OCCCC1=CC=CC=C1 HRDIWAMPNHYPTG-UHFFFAOYSA-N 0.000 claims 1
- SBYZSLNIQGCLLI-UHFFFAOYSA-N n-[2-[6-(4-phenylbutoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C)CCC2=CC=C1OCCCCC1=CC=CC=C1 SBYZSLNIQGCLLI-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702798A ES2331274B1 (es) | 2007-10-25 | 2007-10-25 | Compuesto de indolina. |
| PCT/EP2008/064389 WO2009053440A1 (en) | 2007-10-25 | 2008-10-23 | Indoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500763A JP2011500763A (ja) | 2011-01-06 |
| JP2011500763A5 true JP2011500763A5 (enExample) | 2011-12-08 |
Family
ID=40219359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530462A Abandoned JP2011500763A (ja) | 2007-10-25 | 2008-10-23 | インドリン化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110112148A1 (enExample) |
| EP (1) | EP2203423A1 (enExample) |
| JP (1) | JP2011500763A (enExample) |
| KR (1) | KR20100075518A (enExample) |
| CN (1) | CN101878200A (enExample) |
| AR (1) | AR069003A1 (enExample) |
| AU (1) | AU2008316472A1 (enExample) |
| BR (1) | BRPI0818850A2 (enExample) |
| CA (1) | CA2703453A1 (enExample) |
| CL (1) | CL2008003139A1 (enExample) |
| ES (1) | ES2331274B1 (enExample) |
| MX (1) | MX2010004463A (enExample) |
| RU (1) | RU2010120847A (enExample) |
| TW (1) | TW200934760A (enExample) |
| UY (1) | UY31423A1 (enExample) |
| WO (1) | WO2009053440A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102942516B (zh) * | 2012-11-05 | 2015-02-25 | 宁波大学 | 一种生物碱类化合物及其制备方法和应用 |
| CN103044310B (zh) * | 2013-01-18 | 2015-02-04 | 贵阳医学院 | 二氢吲哚-3-乙酸衍生物、其制备方法以及在药物中的应用 |
| EP3405454B1 (en) * | 2016-01-21 | 2021-12-29 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Indoline derivatives, compositions comprising them and uses thereof |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) * | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| CA2186412A1 (en) * | 1995-10-31 | 1997-05-01 | Katherine S. Takaki | Ethylamino carbazole melatonergic agents |
-
2007
- 2007-10-25 ES ES200702798A patent/ES2331274B1/es not_active Withdrawn - After Issue
-
2008
- 2008-10-23 KR KR1020107008669A patent/KR20100075518A/ko not_active Withdrawn
- 2008-10-23 CA CA2703453A patent/CA2703453A1/en not_active Abandoned
- 2008-10-23 JP JP2010530462A patent/JP2011500763A/ja not_active Abandoned
- 2008-10-23 WO PCT/EP2008/064389 patent/WO2009053440A1/en not_active Ceased
- 2008-10-23 MX MX2010004463A patent/MX2010004463A/es active IP Right Grant
- 2008-10-23 CN CN200880118151XA patent/CN101878200A/zh active Pending
- 2008-10-23 US US12/739,666 patent/US20110112148A1/en not_active Abandoned
- 2008-10-23 AR ARP080104617A patent/AR069003A1/es not_active Application Discontinuation
- 2008-10-23 EP EP08842562A patent/EP2203423A1/en not_active Withdrawn
- 2008-10-23 BR BRPI0818850A patent/BRPI0818850A2/pt not_active IP Right Cessation
- 2008-10-23 RU RU2010120847/04A patent/RU2010120847A/ru not_active Application Discontinuation
- 2008-10-23 AU AU2008316472A patent/AU2008316472A1/en not_active Abandoned
- 2008-10-24 TW TW097140812A patent/TW200934760A/zh unknown
- 2008-10-24 CL CL2008003139A patent/CL2008003139A1/es unknown
- 2008-10-24 UY UY31423A patent/UY31423A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4580371B2 (ja) | アゴメラチンの新規な結晶形態ｉｖ、その製造方法、およびそれを含有する薬学的組成物 | |
| HRP20161672T1 (hr) | Novi kristalni oblik vi agomelatina, postupak priprave i farmaceutski pripravci istog | |
| US8669291B2 (en) | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | |
| ME02024B (me) | Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze | |
| JP4580370B2 (ja) | アゴメラチンの新規な結晶形態ｉｉｉ、その製造方法、およびそれを含有する薬学的組成物 | |
| JP2011500763A5 (enExample) | ||
| JP4575337B2 (ja) | アゴメラチンの新規な結晶形態ｖ、その製造方法、およびそれを含有する薬学的組成物 | |
| US20070203111A1 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| AR086849A1 (es) | Co-cristales de agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| RU2012121684A (ru) | Производные оксазолина для лечения заболеваний цнс | |
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| JP2015521642A5 (enExample) | ||
| JP2011529477A5 (enExample) | ||
| JP2012508275A5 (enExample) | ||
| RU2010120847A (ru) | Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| JP2015521643A5 (enExample) | ||
| RU2011107443A (ru) | Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью | |
| CN1104018A (zh) | 取代的(芳烷基氨基苄基)氨基丙酰胺衍生物及其制备方法 | |
| JP2011500764A5 (enExample) | ||
| HRP20090632T1 (hr) | Novi derivati naftalena, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| AR070003A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CN102977085B (zh) | 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途 | |
| RU2010120846A (ru) | Соединения 2,3-дигидробензофурана, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| AR070004A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AU2015202379B2 (en) | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |